ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1526

Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets

Chamutal Gur1, Postil 1586262, Hagit Peleg3, Suhail Aamar3, Fadi Kharouf3, Anat Elazary3, Yolanda Braun-Moscovici Braun-Moscovici4, Shuang-Yin Wang5 and Ido Amit5, 1Hadassah Medical Center, Hebrew University, Laboratory for Immuno-Genomics, Weizmann Institute of Science, Jerusalem, Israel, 2Rambam Health Care Campus, Technion-Israeli Institute of Technology, Kiriat Mozkin, HaZafon, Israel, 3Hadassah Medical Center, Jerusalem, Israel, 4Rambam Health Care Campus, Technion-Israeli Institute of Technology, Haifa, Israel, 5Laboratory for Immuno-Genomics, Weizmann Institute of Science, Rehovot, Israel

Meeting: ACR Convergence 2020

Keywords: Cell-signalling molecules, Gene Expression, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis, microangiopathy and immune dysregulation. Despite many years of research, the pathogenesis of SSc is poorly understood; there is no approved therapy and biomarkers for early diagnosis, assessment of disease activity, prediction of complications and prognosis. Current technologies that investigate bulk populations of cells lack the depth and resolution needed to define the small skin stromal and immune subsets that drive SSc progression. Advances in the field of single-cell RNA has opened the way for unbiased dissection of complex niches into single cells, and identification of unique cell subtypes, pathways, markers and target genes. Our aims are to understand SSc pathogenesis by comprehensive characterization of stromal and immune cells in the skin and blood of SSc patients and detection of specific intra-skin cell states, pathways, and cell-cell interactions in SSc patients compared to healthy controls.

Methods: We applied the massively parallel single cell RNA-seq (MARS-seq) technique developed in our lab to conduct a comprehensive single-cell analysis of skin stromal and immune cells obtained from punch biopsy together with blood immune cells from 79 SSc patients (44 dSSc, 35 lSSc) at different stages of disease progression, and 35 healthy controls. The perturbed signaling pathways, pathogenic stromal or immune cell subsets are characterized using CyTOF, Immunohistochemistry, Physical Interacting Cell sequencing (PIC-seq), and in vitro functional assays.

Results: We collected data from a total of 49,831 high-quality skin stromal cells, and 61,365 high-quality blood and skin immune cells. Our MetaCell analytical method resulting in a detailed map of 389 meta cells in the immune cell compartment organized into 14 broad lineages (e.g skin T, B and NK cells, Dendritic cells, Monocyte). In the stromal cell compartment, we found 294 meta cells organized into 17 broad lineages including: Fibroblasts, Pericytes, Vascular cells, and other cells.  To our surprise, analysis of the immune cell compartment revealed only minor changes in the cell composition and gene expression in patients compared with controls. In the dermal fibroblast lineage we found a small cluster of cells that were significantly diminished in the SSc patients compared with control. This subset expressed genes associated with fibrosis, vascular remodeling, and most importantly, display stem cell-like phenotypic markers that are different from other known skin stem cells located in the hair follicle and subcutaneous fat. We further found significant increased number of subsets of pericytes and vascular cells in SSc patients compared with controls. Finally, we found known and novel pathways that play crucial roles in SSc pathogenesis.

Conclusion: Our study provides the most comprehensive dataset in single cell resolution in SSc, and suggests a paradigm shift in the understanding of SSc. The MARS-seq can serve as a vehicle for discovering immune-stromal cell crosstalk, for finding new biomarkers for early SSc diagnosis and for tailoring and identification of new therapeutic targets.


Disclosure: C. Gur, None; P. 158626, None; H. Peleg, None; S. Aamar, None; F. Kharouf, None; A. Elazary, None; Y. Braun-Moscovici, None; S. Wang, None; I. Amit, None.

To cite this abstract in AMA style:

Gur C, 158626 P, Peleg H, Aamar S, Kharouf F, Elazary A, Braun-Moscovici Y, Wang S, Amit I. Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/single-cell-analysis-of-skin-and-blood-of-scleroderma-patients-towards-identification-of-new-disease-mechanisms-prognostic-biomarkers-and-potential-therapeutic-targets/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-analysis-of-skin-and-blood-of-scleroderma-patients-towards-identification-of-new-disease-mechanisms-prognostic-biomarkers-and-potential-therapeutic-targets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology